<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2107222324
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CEFAJECT 500 mg IM
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CEFTRIAXONE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        500
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Intramuscular use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Powder for solution for injection/infusion
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        23.8
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="TABUK PHARMACEUTICAL MANUFACTURING CO." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            TABUK PHARMACEUTICAL MANUFACTURING CO.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Abbott Laboratories GmbH
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J01DD04
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Cefaject</strong> contains &nbsp;a &nbsp;medicine &nbsp;called &nbsp;ceftriaxone. &nbsp;This belongs to a group of medicines called antibiotics.</p><p>- <strong>Cefaject</strong> is used to treat infections caused by bacteria.</p><p>- It can be used to treat infections in different parts of the body including the lungs (pneumonia), blood (septicemia), skin, other soft body parts (tissues), bone, and for infections such as meningitis and gonorrhea (a sexually transmitted infection).</p><p>- It &nbsp;can &nbsp;be &nbsp;used &nbsp;to &nbsp;treat &nbsp;infections &nbsp;in &nbsp;people &nbsp;with &nbsp;low numbers of white blood cells (neutropenia).</p><p>- It can also be given before and after operations to stop infections from happening.</p><p>It works by stopping the bacteria from growing properly. This</p><p>causes the bacteria to die.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use Cefaject</strong></p><p>- If you are allergic (hypersensitive) to ceftriaxone (the only ingredient in <strong>Cefaject</strong>).</p><p>- If&nbsp; you &nbsp;are &nbsp;allergic &nbsp;to antibiotics &nbsp;called &nbsp;&lsquo;cephalosporins&rsquo;. These include cefalexin, cefaclor and cefuroxime.</p><p>- If&nbsp; you &nbsp;have &nbsp;had &nbsp;a &nbsp;<strong>sudde</strong><strong>n or &nbsp;severe &nbsp;</strong>allergic &nbsp;reaction to penicillin or similar antibiotics (such as amoxicillin or ﬂucloxacillin).&nbsp;&nbsp; The&nbsp;&nbsp; signs&nbsp;&nbsp; include&nbsp;&nbsp; sudden&nbsp;&nbsp; swelling of&nbsp; the&nbsp; throat&nbsp; or&nbsp; face&nbsp;&nbsp; which&nbsp; might&nbsp; make&nbsp;&nbsp; it&nbsp; difﬁcult to breathe or swallow, sudden swelling of the hands, feet and ankles, and a severe rash that develops quickly.</p><p>- If you are allergic to lidocaine and you are to be given</p><p><strong>Cefaject</strong> as an injection into a muscle.</p><p>You must not be given <strong>Cefaject</strong> if any of the above apply to</p><p>you. If you are not sure, talk to your doctor or nurse before having <strong>Cefaject</strong>.</p><p><strong>Cefaject</strong><strong> must </strong><strong>not be given to babies if:</strong></p><p>- The baby is premature.</p><p>- The baby is newborn (up to 28 days) and has certain blood problems or jaundice (yellowing of the skin or the whites of the eyes) or is about to be given another injection that contains calcium.</p><p><strong>T</strong><strong>ake special care with Cefaject</strong></p><p>Check&nbsp; &nbsp;with&nbsp; &nbsp;your&nbsp; &nbsp;doctor&nbsp; &nbsp;or&nbsp; &nbsp;nurse&nbsp; &nbsp;before&nbsp; &nbsp;having</p><p><strong>Cefaject</strong> if:</p><p>- You have had a <strong>mild </strong>allergic reaction to penicillin or similar antibiotics&nbsp; (such&nbsp; as&nbsp; a&nbsp; skin&nbsp; rash&nbsp; which&nbsp; may&nbsp; have&nbsp; been itchy).</p><p>- You are allergic to anything not already mentioned in this</p><p>leaﬂet.</p><p>- You have asthma.</p><p>- You have recently received or are about to receive calcium.</p><p>- You have ever had problems with your gut, in particular</p><p>colitis (inﬂammation &nbsp;of the bowel).</p><p>- You have liver or kidney problems.</p><p>- You have other illnesses, such as blood problems.</p><p>- You are on a low sodium diet.</p><p>If any of the above apply to you, or if you are not sure, talk</p><p>to your doctor or nurse before you have <strong>Cefaject</strong>.</p><p><strong>T</strong><strong>aking other medicines</strong></p><p>Please tell your doctor or nurse if you are taking or have recently taken any other medicines. This includes medicines that you buy without a prescription and herbal medicines. This is because <strong>Cefaject</strong> can affect the way some medicines work. Also some medicines can affect the way <strong>Cefaject</strong> works.</p><p>In particular, tell your doctor or nurse if you are taking any of the following medicines:</p><p>- Oral contraceptives (the pill). <strong>Cefaject</strong> can stop the pill from working, so you should use extra barrier contraception methods (such as condoms) while you are taking <strong>Cefaject</strong> and for one month afterwards.</p><p>- Chloramphenicol (used to treat infections, particularly of the eyes).</p><p>- Anticoagulants (medicines used to thin the blood).</p><p>- Probenecid (used to treat gout).</p><p>- Amsacrine (an anti-cancer medicine).</p><p>- Fluconazole (an anti-fungal medicine).</p><p>- Vancomycin or other antibiotics (used to treat infections).</p><p><strong>Pregnancy and breast-feeding</strong></p><p>Talk to your doctor before taking this medicine if you are pregnant, might become pregnant, or are breast-feeding. <strong>Driving and using machines</strong></p><p><strong>Cefaject</strong> can cause dizziness. Talk to your doctor if any of these happen to you and do not drive or use any tools or machines.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Cefaject</strong> is given by slow IV or deep IM injection into the &nbsp;once a day (every 24 hours). Treatment is to be continued for at least two days after the symptoms of disease have disappeared.</p><p><strong>Adults and children </strong><strong>over 12 years:</strong></p><p>Usual dose is 1-2 g daily. The dose can be increased to</p><p>4 &nbsp;g/day &nbsp;in &nbsp;severe &nbsp;cases &nbsp;or &nbsp;in &nbsp;infections &nbsp;caused &nbsp;by moderately sensitive organisms.</p><p>The usual treatment for an infection called &lsquo;gonorrhea&rsquo; is one dose of 250 mg, given as an injection into a muscle.</p><p><strong>Infants and children </strong><strong>(3 weeks to 12 years):</strong></p><p>20-80 mg/kg of body weight daily.</p><p>If the body weight is 50 kg or more, use the adult dosage. Doses above 50 mg/kg should be administered by intravenous infusion only.</p><p><strong>Neonates </strong><strong>(up to 2 weeks):</strong></p><p>20-50 mg/kg of body weight daily.</p><p><strong>People with liver and kidney problems</strong></p><p>If you have problems with your liver and kidneys, you may be given a lower dose. You may need to have blood tests to check that you are getting the dose you need.</p><p><strong>If you are given too much Cefaject</strong></p><p>If you think you have been given too much <strong>Cefaject</strong>, tell your doctor or nurse.</p><p>If &nbsp;you &nbsp;have &nbsp;any &nbsp;further &nbsp;questions &nbsp;on &nbsp;the &nbsp;use &nbsp;of &nbsp;this medicine, ask your doctor or nurse.</p><p><strong>Reconstitution:</strong></p><p><strong>For Cefaject</strong><strong> 500 </strong><strong>mg IM injection: </strong>Dissolve the contents of</p><p>one &nbsp;vial &nbsp;using &nbsp;2 &nbsp;ml &nbsp;from &nbsp;the &nbsp;lidocaine &nbsp;hydrochloride</p><p>ampoule.</p><p><strong>For Cefaject</strong><strong> 500 </strong><strong>mg IV injection: </strong>Dissolve the contents of one vial using 5 ml of sterile water for injection.</p><p><strong>For Cefaject</strong><strong> 1000 mg IM injection: </strong>Dissolve the contents of one vial using 3.5 ml from the lidocaine hydrochloride ampoule. <strong>For Cefaject</strong><strong> 1000 mg IV injection: </strong>Dissolve the contents of one vial using 10 ml of sterile water for injection.</p><p>The reconstituted solution color is pale yellow to amber depending on concentration and storage duration.</p><p>For IV infusion, use a calcium free infusion solution such as: Sodium chloride 0.9%, dextrose 5% or 10%, levulose 5%</p><p>.......etc.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like &nbsp;all &nbsp;medicines, &nbsp;<strong>Cefaject</strong> can &nbsp;cause &nbsp;side &nbsp;effects, although not everyone will get them.</p><p>The following side effects may happen with this medicine.</p><p><strong>Severe allergic reactions </strong>(uncommon, affect less than 1 in</p><p>100 people)</p><p>If you have a severe allergic reaction, <strong>tell a doctor straight away</strong>.</p><p>The signs may include:</p><p>- Sudden swelling of the face, throat, lips or mouth. This can</p><p>make it difﬁcult to breathe or swallow.</p><p>- Sudden swelling of the hands, feet and ankles.</p><p><strong>Sever</strong><strong>e &nbsp;skin &nbsp;rashes &nbsp;</strong>(very &nbsp;rare, &nbsp;affect &nbsp;less &nbsp;than &nbsp;1 &nbsp;in</p><p>10,000 people)</p><p>If you get a severe skin rash, <strong>tell a doctor straight away</strong>.</p><p>- The signs may include a severe rash that develops quickly, with blisters or peeling of the skin and possibly blisters in the mouth.</p><p><strong>Other possible side effects:</strong></p><p><strong>Common (affect </strong><strong>less than 1 in 10 people)</strong></p><p>- Loose stools or diarrhea.</p><p>- Feeling sick or being sick.</p><p><strong>Uncommon (affect </strong><strong>less than 1 in 100 people)</strong></p><p>- Other skin &nbsp;reactions. These &nbsp;include &nbsp;a &nbsp;rash &nbsp;which &nbsp;may cover a lot of your body, a lumpy rash (hives), feeling itchy and swelling.</p><p><strong>Rare (affect </strong><strong>less than 1 in 1,000 people)</strong></p><p>- Other types of infection, such as those caused by fungi and yeasts (for example, thrush).</p><p>- Blood problems. The signs include feeling tired, bruising easily, being short of breath and nosebleeds.</p><p>- Headache.</p><p>- Feeling dizzy.</p><p>- A sore mouth.</p><p>- Inﬂammation&nbsp; of the tongue (glossitis).&nbsp; The&nbsp; signs&nbsp; include</p><p>swelling, redness and soreness of the tongue.</p><p>- Liver problems (shown in a blood test).</p><p>- Problems &nbsp;with &nbsp;your &nbsp;gallbladder &nbsp;which &nbsp;may &nbsp;cause &nbsp;pain, feeling sick and being sick.</p><p>- Kidney problems. These may affect the amount of water (urine) that you pass. Some people pass less water than usual. Very rarely, people stop passing water altogether.</p><p>- Blood or sugar in your urine.</p><p>- Pain or a burning feeling along the vein where <strong>Cefaject</strong></p><p>has been given.</p><p>- Pain where the injection was given.</p><p>- A high temperature (fever) or shivering.</p><p><strong>V</strong><strong>ery rare (affect less than 1 in 10,000 people)</strong></p><p>- Positive results in a Coombs&rsquo; test (a test for some blood problems).</p><p>- Problems with the way your blood clots. The signs include bruising easily and pain and swelling of your joints.</p><p>- Changes in the numbers of white cells in your blood. The signs include a sudden high temperature (fever), shivering and a sore throat.</p><p>- Inﬂammation&nbsp; of&nbsp; the&nbsp; pancreas&nbsp; (pancreatitis).&nbsp;&nbsp; The&nbsp; signs include severe pain in the stomach which spreads to your back.</p><p>- Inﬂammation&nbsp; of the large bowel (colon).&nbsp; The signs include diarrhea, usually with blood and mucus, stomach pain and fever.</p><p>If any of the side effects become serious or troublesome, or if you notice any side effects not listed in this leaﬂet, please tell your doctor or nurse.</p><p><strong>T</strong><strong>o report any side effect(s):</strong></p><p><strong>&bull; </strong><strong>Saudi Arabia:</strong></p><p>National Pharmacovigilance and Drug Safety Center (NPC)</p><p>Fax: +966-11-205-7662</p><p>Call NPC at +966-11-2038222</p><p>Exts: 2317-2356-2353-2354-2334-2340</p><p>Toll free phone: 8002490000</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: www.sfda.gov.sa/npc</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of reach of children. Store below 30&deg;C.</p><p>Keep the vial in the carton until content is consumed.</p><p><strong>After Reconstitution:</strong></p><p>The reconstituted solution is stable for 6 hours at room</p><p>temperature&nbsp; (below &nbsp;30&deg;C)&nbsp; or&nbsp; for 24&nbsp; hours &nbsp;in &nbsp;refrigerator</p><p>(2-8&deg;C).</p><p>Do not use beyond the expiry date or if the product shows any sign of deterioration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Cefaject</strong><strong> contains:</strong></p><p><strong>Cefaject</strong><strong> 500 </strong><strong>mg IM: </strong>The vial contains: Sterile ceftriaxone</p><p>sodium (USP) equivalent to 500 mg ceftriaxone.</p><p>The&nbsp; &nbsp;ampoule&nbsp; &nbsp;contains:&nbsp; &nbsp;5&nbsp; &nbsp;ml&nbsp; &nbsp;of&nbsp; &nbsp;1%&nbsp; &nbsp;w/v&nbsp; &nbsp;lidocaine hydrochloride injection (USP).</p><p><strong>Cefaject</strong><strong> 500 mg IV: </strong>The vial contains: Sterile ceftriaxone sodium (USP) equivalent to 500 mg ceftriaxone.</p><p>The ampoule contains: 5 ml sterile water for injection. <strong>Cefaject</strong><strong> 1000mg IM: </strong>The &nbsp;vial &nbsp;contains: &nbsp;Sterile &nbsp;ceftriaxone sodium (USP) equivalent to 1000 mg ceftriaxone.</p><p>The&nbsp; &nbsp;ampoule&nbsp; &nbsp;contains:&nbsp; &nbsp;5&nbsp; &nbsp;ml&nbsp; &nbsp;of&nbsp; &nbsp;1%&nbsp; &nbsp;w/v&nbsp; &nbsp;lidocaine hydrochloride injection (USP).</p><p><strong>Cefaject</strong><strong> 1000 mg IV: </strong>The &nbsp;vial &nbsp;contains: &nbsp;Sterile &nbsp;ceftriaxone sodium (USP) equivalent to 1000 mg ceftriaxone.</p><p>The ampoule contains: 10 ml sterile water for injection.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Presentations:
Cefaject 500 mg IM: A carton containing one vial and one
5 ml ampoule of lidocaine hydrochloride solution.
Cefaject 500 mg IV: A carton containing one vial and one
5 ml ampoule of sterile water for injection.
Cefaject 1000 mg IM: A carton containing one vial and one 5 ml ampoule of lidocaine hydrochloride solution.
Cefaject 1000 mg IV: A carton containing one vial and one 10 ml ampoule of sterile water for injection.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MAH:</p><p><strong>Abbott Laboratories GmbH, Germany</strong></p><p><strong>Manufactured </strong><strong>by:</strong></p><p><strong>T</strong><strong>ABUK PHARMACEUTICAL MANUFACTURING COMPANY,</strong></p><p><strong>MADINA ROAD, P.O. Box 3633, TABUK-SAUDI ARABIA.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                JULY 2016
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL"><strong>1.&nbsp; </strong>يحتوي<strong> سيفاجيكت</strong> على دواء يعرف بسيفترياكسون، وينتمي إلى مجموعة من الأدوية تعرف بالمضادات الحيوية .</p><p dir="RTL">-&nbsp;&nbsp; يستعمل <strong>سيفاجيكت</strong> لعلاج الالتهابات التي تسببها البكتيريا.</p><p dir="RTL">-&nbsp;&nbsp; قد يستعمل لعلاج الالتهابات في أجزاء مختلفة من الجسم بما في ذلك الرئتين (التهاب الرئة )، الدم (تسمم الدم) ، الجلد ، أجزاء الجسم&nbsp; الرخوة الأخرى (الأنسجة)، العظم، وللالتهابات مثل التهاب السحايا وداء السيلان (التهاب ينتقل عن طريق الجنس ).</p><p dir="RTL">-&nbsp;&nbsp; قد يستعمل لعلاج الالتهابات عند الأشخاص الذين يعانون من انخفاض تعدد خلايا الدم البيضاء (قلة العدلات).</p><p dir="RTL">-&nbsp;&nbsp; ويمكن أيضاً أن يعطى قبل وبعد العمليات الجراحية للوقاية من حدوث الالتهابات .</p><p dir="RTL">انه يعمل عن طريق وقف نمو البكتيريا بشكل صحيح وذلك يسبب موت البكتيريا.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">موانع إعطاء <strong>سيفاجيكت</strong></p><p dir="RTL">-&nbsp;&nbsp; إذا كنت تعاني من الحساسية (فرط الحساسية) ليسفترياكسون (المكون الوحيد في <strong>سيفاجيكت</strong>).</p><p dir="RTL">-&nbsp;&nbsp; إذا كنت تعاني من الحساسية لمضادات حيوية تعرف &quot;بالسيفالوسبورينات &quot;، تتضمن سيفالكسين ، سيفاكلور وسيفوروكسيم.</p><p dir="RTL">-&nbsp;&nbsp; إذا عانيت في السابق من تفاعل تحسسي مفاجئ أو حاد للبنسيلين أو لمضادات&nbsp; حيوية مشابهة (مثل أموكسيسيلين أو&nbsp; فلوكلو كساسيلين ). تتضمن العلامات تورم مفاجئ في الحلق (البلعوم ) أو الوجه الذي قد يسبب صعوبة في التنفس أو البلع ، تورم مفاجئ في اليدين ، القدمين&nbsp; والكاحلين ، طفح حاد يتطور بسرعة .</p><p dir="RTL">-&nbsp;&nbsp; اذا كنت تعاني من الحساسية لليدوكائين وسيتم إعطاؤك حقن سيفاجيكت في العضل.</p><p dir="RTL">يجب عدم إعطاء سيفاجيكت إذا كان أي مما ذكر في الأعلى ينطبق عليك . إذا لم تكن متأكداً ، تحدث مع طبيبك أو الممرض قبل إعطائك <strong>سيفاجيكت</strong>.</p><p dir="RTL"><strong>يجب عدم إعطاء سيفاجيكت للأطفال في الحالات التالية :</strong></p><p dir="RTL">-&nbsp;&nbsp; الأطفال الخدج</p><p dir="RTL">-&nbsp;&nbsp; الأطفال حديثي الولادة (لغاية &nbsp;28 يوماً من العمر) ويعانون من بعض مشاكل&nbsp; في الدم أو يرقان (اصفرار الجلد أو المنطقة البيضاء في العيون ) أو سيتم إعطاؤه حقن آخرى تحتوي على الكالسيوم .</p><p dir="RTL"><strong>الاحتياط عند إعطاء سيفاجيكت</strong><br />تأكد من طبيبك أو الممرض قبل إعطاء <strong>سيفاجيكت</strong>:</p><p dir="RTL">-&nbsp;&nbsp; إذا عانيت في السابق من تفاعل تحسسي معتدل للبنسيلين أو لمضادات حيوية مشابهة (مثل طفح جلدي وقد يرافقه حكه ).</p><p dir="RTL">-&nbsp;&nbsp; إذا كنت تعاني من الحساسية لأي شيء لم يذكر في هذه النشرة.</p><p dir="RTL">-&nbsp;&nbsp; أذا كنت تعاني من الربو.</p><p dir="RTL">-&nbsp;&nbsp; إذا تم إعطاؤك مؤخراً أو سيتم إعطاؤك كالسيوم .</p><p dir="RTL">-&nbsp;&nbsp; إذا عانيت في السابق من مشاكل في الأمعاء، خاصة التهاب القولون (التهاب الأمعاء ).</p><p dir="RTL">-&nbsp;&nbsp; إذا كنت تعاني من مشاكل في الكبد أو الكلي.</p><p dir="RTL">-&nbsp;&nbsp; إذا كنت تعاني من أمراض أخرى ، مثل مشاكل الدم.</p><p dir="RTL">-&nbsp;&nbsp; إذا كنت تتبع نظاماً غذائياً قيل الصوديوم.</p><p dir="RTL">إذا كان أي مما ذكر في الأعلى ينطبق عليك ، أو إذا لم تكن متأكداً تحدث مع طبيبك و الممرض قبل إعطائك <strong>سيفاجيكت</strong>.</p><p>&nbsp;</p><p dir="RTL"><strong>تناول أدوية أخرى</strong></p><p dir="RTL">الرجاء إخبار طبيبك أو الممرض إذا كنت تتناول أو تناولت مؤخراً أي أدوية أخرى ، يتضمن ذلك الأدوية التي يتم الحصول عليها بدون وصفة طبية والأدوية العشبية وذلك لأن <strong>سيفاجيكت</strong> يمكن أن يؤثر على طريقة عمل بعض الأدوية، أيضاً يمكن لبعض الأدوية أن تؤثر على طريقة عمل <strong>سيفاجيكت</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>&nbsp;بشكل خاص ، أخبر طبيبك أو الممرض إذا كنت تتناول أي من الأدوية التالية :</strong></p><p dir="RTL">-&nbsp;&nbsp; موانع الحمل التي يتم تناولها عن طريق الفم (الأقراص ). قد يبطل <strong>سيفاجيكت</strong> مفعول هذه الأقراص ، لذلك يجب استعمال وسائل اضافية لمنع الحمل (مثل الواقي الذكري ) اثناء فترة استعمال <strong>سيفاجيكت</strong> ولمدة شهر واحد بعد إنتهاء فترة العلاج.</p><p dir="RTL">-&nbsp;&nbsp; كلورامفينيكول (يستعمل لعلاج الااتهابات وخاصة في العيون).</p><p dir="RTL">-&nbsp;&nbsp; مضادات التجلط (أدوية تستعمل للوقاية من تجلط الدم ).</p><p dir="RTL">-&nbsp;&nbsp; بروبنسيد (يستعمل لعلاج النقرس ).</p><p dir="RTL">-&nbsp;&nbsp; أمساكرين (دواء مضاد للسرطان).</p><p dir="RTL">-&nbsp;&nbsp; فلوكونازول(دواء مضاد للفطريات ).</p><p dir="RTL">-&nbsp;&nbsp; فانكومايسين أو مضادات حيوية أخرى (تستعمل لعلاج الالتهابات ).</p><p dir="RTL"><strong>الحمل والإرضاع :</strong></p><p dir="RTL">تحدثي مع طبيبك قبل استعمال هذا الدواء إذا كنت حامل ، أو من المتوقع حصول الحمل ، أو مرضعة.</p><p dir="RTL"><strong>قيادة المركبات واستخدام الآلات .</strong></p><p dir="RTL">قد يسبب <strong>سيفاجيكت</strong> شعور بالدوار . تحدث مع طبيبك إذا حصل لديك أي من ذلك وتجنب قيادة المركبات أو استخدم أي أدوات أو آلات.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يعطي <strong>سيفاجيكت</strong> عن طريق الحقن الوريدي البطيء أو الحقن العضلي العميق في العضلات الألوية مرة واحدة يومياً (كل 24 ساعة ) يجب أن يستمر العلاج لمدة يومين على الأقل بعد اختفاء أعراض المرض .</p><p dir="RTL"><strong>البالغون والأطفال أكبر من 12 سنة : </strong></p><p dir="RTL">الجرعة الاعتيادية هي&nbsp; 1- 2 جم يومياً ، ويمكن زيادتها&nbsp; 4 جم يومياً في الحالات الحادة أو في الالتهابات الناتجة عن الجراثيم متوسطة الحساسية لسيفترياكسون.<br />العلاج المعتاد&nbsp; لالتهاب &quot;داء السيلان &quot; هي جرعة واحدة 250 ملجم تعطي على شكل حقن داخل العضل .</p><p dir="RTL"><strong>الرضع والأطفال (من 3 أسابيع إلى 12 سنة ):</strong><br />20-80 ملجم / كجم من وزن الجسم يومياً . يجب استعمال جرعات البالغين للأطفال الذين تبلغ أوزانهم 50 كجم أو اكثر . يجب إعطاء الجرعات التي تتجاوز 50 ملجم / كجم&nbsp; عن طريق التسريب الوريدي فقط .</p><p dir="RTL"><strong>حديثي الولادة (حتى اسبوعين ): </strong></p><p dir="RTL">20-50 ملجم / كجم من وزن الجسم&nbsp; يومياً .</p><p dir="RTL"><strong>الأشخاص الذين يعانون من مشاكل في الكبد والكلى .</strong><br />إذا كنت تعاني من مشاكل في الكبد والكلى ، قد يتم إعطاؤك جرعة أقل . قد تحتاج لإجراء فحصوات للدم للتأكد من أنك تحصل على الجرعة التي تحتاج اليها .</p><p dir="RTL"><strong>إذا تم إعطاؤك سيفاجيكت أكثر مما يجب</strong> .<br />إذا كنت تعتقد بأنك قد أعطيت أكثر مما يجب من <strong>سيفاجيكت</strong> ، اخبر طبيبك أو الممرض .<br />إذا كان لديك أي اسئلة إضافية عن استعمال هذا الدواء ، اسأل طبيبك أو الممرض. <strong>التحضير :<br />سيفاجيكت</strong> 500 ملجم للحقن العضلي : تذاب محتويات الزجاجة بواسطة 2 مل من أمبولة هيدروكلويد الليدوكانين.<br /><strong>سيفاجيكت</strong> 500 ملجم للحقن الوريدي : تذاب محتويات الزجاجة بواسطة 5 مل من&nbsp; أمبولة الماء المعقم للحقن .<br /><strong>سيفاجيكت</strong> 1000 ملجم للحقن العضلي : تذاب محتويات الزجاجة بواسطة 3.5 مل من أمبولة هيدروكلوريد .<br /><strong>سيفاجيكت</strong> 1000 ملجم للحقن الوريدي : تذاب محتويات الزجاجة بواسطة 10 مل من أمبولة الماء المعقم للحقن<br />يكون لون المحلول المحضر أصفر شاحباً إلى أصفر مائل إلى البني حسب التركيز ومدة الحفظ.<br />في حالة الإعطاء عن طريق التسريب الوريدي ، يستعمل&nbsp; محلول تسريب خال من الكالسيوم مثل : محلول كلوريد الصوديوم&nbsp; 0.9% ، محلول الدكستروز 5%&nbsp; أو 10% ، محلول الليفولوز 5% .... الخ .</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>&nbsp;</strong>مثل كل الأدوية ، قد يسبب <strong>سيفاجيكت</strong>&nbsp; آثار جانبية ، على الرغم من عدم حدوثها لدى الجميع . الآثار الجانبية التالية قد تحدث مع هذا الدواء.<br /><strong>تفاعلات تحسسية حادة</strong> (غير شائعة ، تؤثر على أقل 1من كل 100شخص ) إذا عانيت من تفاعل تحسسي حاد، أخيبر الطبيب فوراً . قد تتضمن العلامات&nbsp; ما يلي:</p><p dir="RTL">- تورم مفاجئ في الوجه ، الحلق (البلعوم ) الشفاه أو الفم ، وقد يسبب هذا صعوبة في التنفس أو البلع.</p><p dir="RTL">- تورم مفاجئ في اليدين ، القدمين والكاحلين .</p><p dir="RTL"><strong>طفح جلدي حاد </strong>(نادر جداً، يؤثر على أقل من 1 من كل 10000 شخص )<strong> </strong><br />إذا حصل لديك طفح جلدي حاد، اخبر الطبيب فوراً.</p><p dir="RTL">- قد تتضمن العلامات طفح حاد يتطور بسرعة ، مع ظهور تنفط أو قشر للجلد ، من الممكن حصول نفطات في الفم .<br /><strong>آثار جانبية محتملة أخرى:</strong><br /><strong>شائعة (تؤثر على أقل من 1 من كل 10 شخص )</strong></p><p dir="RTL">- براز رخو أو إسهال .</p><p dir="RTL">- شعور بالغثيان أو القيء.<br /><strong>غير شائعة (تؤثر على أقل من 1 من كل 100 شخص )</strong></p><p dir="RTL">- تفاعلات جلدية أخرى. تتضمن طفح قد يغطي مساحة كبيرة من الجسم ،وطفح مع بروز كتل على سطح الجلد (الشرى)، شعور بالحكة وتورم.<br /><strong>نادرة&nbsp; (تؤثر على أقل من 1 من كل 1000 شخص )</strong></p><p dir="RTL">- أنواع أخرى من الالتهابات ، مثل تلك التي تسببها الفطريات والخمائر (مثل مرض القلاع )</p><p dir="RTL">- مشاكل الدم : تتضمن العلامات الشعور بالتعب ، التعرض للكدمات بسهولة ، ،قصر التنفس &nbsp;ونزيف الأنف .</p><p dir="RTL">- صداع .</p><p dir="RTL">- شعور بالدوار .</p><p dir="RTL">- تقرح الفم .</p><p dir="RTL">- التهاب اللسان : تتضمن العلامات تورم ، احمرار وتقرح اللسان .</p><p dir="RTL">- مشاكل الكبد (تظهر في فحص الدم ).</p><p dir="RTL">- مشاكل في المرارة &nbsp;قد تسبب الألم ، الشعور بالغثيان والقيء.</p><p dir="RTL">- مشاكل في الكلى&nbsp; قد تؤثر على كمية البول التي تخرجها. بعض الأشخاص قد يخرجون كمية بول اقل من المعتاد . نادر جداً ، ما يتوقف خروج البول تماماً.</p><p dir="RTL">- ظهور دم أو سكر في البول .</p><p dir="RTL">- شعور بالألم أو الحرقة على طول الوريد عند موضع إعطاء سيفاجيكت .</p><p dir="RTL">- ألم عند موضع إعطاء الحقن .</p><p dir="RTL">- ارتفاع درجة الحرارة (حمى) أو قشعريرة.</p><p dir="RTL"><strong>نادرة جداً (تؤثر على اقل من 1 من كل 10000 شخص )</strong></p><p dir="RTL">- نتائج إيجابية في فحص كومب (هو فحص لبعض مشاكل الدم ).</p><p dir="RTL">- مشاكل في طريقة تجلط الدم . تتضمن العلامات التعرض للكدمات بسهولة وألم وتورم المفاصل .</p><p dir="RTL">- تغيرات في أعداد خلايا الدم البيضاء تتضمن العلامات ارتفاع مفاجئ في درجة الحرارة (حمى) قشعريرة والتهاب الحلق.</p><p dir="RTL">- التهاب البنكرياس : تتضمن العلامات ألم حاد في المعدة والذي ينتشر إلى الظهر</p><p dir="RTL">- التهاب الأمعاء الغليظة (القولون ) تتضمن العلامات إسهال يصاحبه عادة ظهور دم ومخاط ، ألم في المعدة وحمى .</p><p dir="RTL">- &nbsp;&nbsp;إذا زادت حدة أي من الآثار الجانبية أو أصبحت تزعجك أو اذا لاحظت اثار جانبية غير مذكورة في هذه النشرة ، الرجاء أن تخبر طبيبك أو الصيدلاني .</p><p dir="RTL"><strong>القيام بالإبلاغ عن أي من الأعراض الجانبية :</strong></p><p dir="RTL">المملكة العربية السعودية :المركز الوطني للتيقظ والسلامة الدوائية<br />فاكس : 7662- 205&ndash;11-966+<br />للاتصال بالإدارة التنفيذية للتيقظ وإدارة الأزمات<br />هاتف :2038222-11-966+<br />تحويلة :2340-2334-2354-2353-2356-2317<br />الهاتف المجاني : 8002490000<br />البريد الإلكتروني : NPC.DRUG@SFDA.GOV.SA<br />الموقع الالكتروني : www.sfda.gov.sa/npc</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيداً عن الأطفال.</p><p dir="RTL">يحفظ في درجة حرارة أقل من 30&deg;م.<br />يجب حفظ الزجاجة في العبوة لحين استنفاذ محتوياتها.<br /><strong>بعد التحضير :</strong><br />يبقى المحلول المحضر ثابتاً لمدة 24 ساعة في درجة حرارة الغرفة (أقل من 30&deg;م) أو لمدة 24 ساعة في الثلاجة (2-8&deg;م).<br />لاتستعمل الدواء بعد انتهاء مدة الصلاحية أو عند ملاحظة أي علامة تلف فيه.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>ماذا يحتوي سيفاجيكت :<br />سيفاجيكت 500 ملجم للحقن العضلي</strong> :&nbsp; تحتوي الزجاجة ما يعادل 500 ملجم سيفترياكسون صوديوم معقم (دستور الأدوية الأمريكي ) ما يعادل 500 ملجم سيفترياكسون.<br />تحتوي الأمبولة على : 5 مل هيدروكلوريد الليدوكائين للحقن (دستور الأدوية الأمريكي ) 1% وزن / حجم .<br /><strong>سيفاجيكت 500 ملجم للحق الوريدي</strong> <strong>:</strong> تحتوي الزجاجة على سيفترياكسون صوديوم معقم (دستور الأدوية الأمريكي ) ما يعادل 500 ملجم سيفترياكسون.<br />تحتوي الأمبولة على :5 مل ماء معقم&nbsp; للحقن .<br /><strong>سيفاجيكت 1000 مجم للحقن العضلي :</strong> تحتوي الزجاجة على سيفترياكسون صوديوم معقم (دستور الأدوية الأمريكي ) مايعادل 1000 مجم سيفترياكسون.<br />تحتوي الأمبولة على : 5 مل هيدروكلوريد&nbsp; الليدوكائين للحقن (دستور الأدوية الأمريكي ) 1% وزن / حجم.<br /><strong>سيفاجيكت 1000 مجم للحقن الوريدي</strong> <strong>:</strong> تحتوي الزجاجة على سيفترياكسون صوديوم معقم (دستور الأدوية الأمريكي ) مايعادل 1000 مجم سيفترياكسون. تحتوي الأمبولة على : 10 مل ماء معقم للحقن .<br /><br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>سيفاجيكت 500 ملجم للحقن العضلي :</strong> عبوة تحتوي على زجاجة واحدة مع أمبولة تحتوي 5 مل من محلول هيدروكلوريد الليدوكائين .</p><p dir="RTL"><strong>سيفاجيكت 500 ملجم للحقن الوريدي :</strong> عبوة تحتوي على زجاجة واحدة مع أمبولة تحتوي 5 مل ماء معقم&nbsp; للحقن .<br /><strong>سيفاجيكت1000 ملجم للحقن العضلي :</strong> عبوة تحتوي على زجاجة واحدة مع&nbsp; أمبولة تحتوي 5 مل من محلول هيدروكلوريد الليدوكائين.<br /><strong>سيفاجيكت 1000 للحقن الوريدي :</strong> عبوة تحتوي على زجاجة واحدة مع أمبولة تحتوي 10 مل ماء معقم للحقن .</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>مالك حق التسويق:</p><p>شركة أبوت لابوراتوريز، ألمانيا</p><p>&nbsp;</p><p>الشركة المصنعه:</p><p dir="RTL">شركة تبوك للصناعات الدوائية،</p><p dir="RTL">طريق المدينة، ص.ب 3633، تبوك &ndash; المملكة العربية السعودية.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            يوليو 2016
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Cefaject 500 mg IM Injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The vial contains: Sterile ceftriaxone sodium (USP) equivalent to 500 mg ceftriaxone.
The ampoule contains: 5 ml of 1% w/v lidocaine hydrochloride injection (USP).
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Before constitution:
Glass vial containing white to yellowish-orange crystalline powder with rubber bung with aluminum
seal with flip off
After constitution :
Clear, pale yellow colored solution
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ceftriaxone sodium is a broad-spectrum bactericidal cephalosporin antibiotic. Ceftriaxone is active in<br />vitro against a wide range of Gram-positive and Gram-negative organisms, which include &beta;-lactamase<br />producing strains.<br />Ceftriaxone is indicated in the treatment of the following infections either before the infecting organism<br />has been identified or when known to be caused by bacteria of established sensitivity.<br />Pneumonia<br />Septicaemia<br />Meningitis<br />Skin and soft tissue infections<br />Infections in neutropenic patients<br />Gonorrhoea<br />Peri-operative prophylaxis of infections associated with surgery<br />Treatment may be started before the results of susceptibility tests are known.<br />Consideration should be given to official guidance on the appropriate use of antibacterial agents.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ceftriaxone may be administered by deep intramuscular injection, or as a slow intravenous injection,<br />after reconstitution of the solution according to the directions given below. The dosage and mode of<br />administration should be determined by the severity of the infection, susceptibility of the causative<br />organism and the patient&#39;s condition. Under most circumstances a once-daily dose or, in the specified<br />indications, one dose will give satisfactory therapeutic results.<br />Diluents containing calcium, (e.g. Ringer&#39;s solution or Hartmann&#39;s solution), should not be used to<br />reconstitute ceftriaxone vials or to further dilute a reconstituted vial for IV administration because a<br />precipitate can form. Precipitation of ceftriaxone-calcium can also occur when ceftriaxone is mixed<br />with calcium-containing solutions in the same IV administration line. Therefore, ceftriaxone and<br />calcium-containing solutions must not be mixed or administered simultaneously (see sections 4.3, 4.4<br />and 6.2).<br />Intramuscular injection: 1g ceftriaxone should be dissolved in 3.5ml of 1% Lidocaine Injection BP. &amp;<br />500 mg ceftriaxone should be dissolved in 2 ml of 1% Lidocaine injection.The solution should be<br />administered by deep intramuscular injection. Doses greater than 1g should be divided and injected at<br />more than one site.<br />Intravenous injection: 1g ceftriaxone should be dissolved in 10ml of Water for Injections PhEur. &amp; 500<br />mg ceftriaxone should be dissolved in 5ml of water for injection. The injection should be administered<br />over at least 2-4 minutes, directly into the vein or via the tubing of an intravenous infusion.<br />Adults and children 12 years and over:<br />Standard therapeutic dosage: 1g once daily.<br />Severe infections: 2-4 g daily, normally as a once daily dose.<br />The duration of therapy varies according to the course of the disease. As with antibiotic therapy in<br />general, administration of ceftriaxone should be continued for a minimum of 48 to 72 hours after the<br />patient has become afebrile or evidence of bacterial eradication has been obtained.</p><p>Acute, uncomplicated gonorrhoea: One dose of 250mg intramuscularly should be administered.<br />Simultaneous administration of probenecid is not indicated.<br />Peri-operative prophylaxis: Usually one dose of 1g given by intramuscular or slow intravenous<br />injection. In colorectal surgery, 2g should be given intramuscularly (in divided doses at different<br />injection sites), by slow intravenous injection or by slow intravenous infusion, in conjunction with a<br />suitable agent against anaerobic bacteria.<br />Elderly: These dosages do not require modification in elderly patients provided that renal and hepatic<br />function are satisfactory (see below).<br />In the neonate, the intravenous dose should be given over 60 minutes to reduce the displacement of<br />bilirubin from albumin, thereby reducing the potential risk of bilirubin encephalopathy (see Special<br />warning and precautions for use).</p><p><br />Children under 12 years</p><p>Standard therapeutic dosage: 20-50mg/kg body-weight once daily.<br />Up to 80mg/kg body-weight daily may be given in severe infections, except in premature neonates<br />where a daily dosage of 50mg/kg should not be exceeded. For children with body weights of 50kg or<br />more, the usual dosage should be used. Doses of 50mg/kg or over should be given by slow intravenous<br />infusion over at least 30 minutes. Doses greater than 80mg/kg body weight should be avoided because<br />of the increased risk of biliary precipitates.<br />Renal and hepatic impairment: In patients with impaired renal function, there is no need to reduce the<br />dosage of ceftriaxone provided liver function is intact. Only in cases of pre-terminal renal failure<br />(creatinine clearance &lt;10ml per minute) should the daily dosage be limited to 2g or less.<br />In patients with liver damage there is no need for the dosage to be reduced provided renal function is<br />intact.<br />In severe renal impairment accompanied by hepatic insufficiency, the plasma concentration of<br />ceftriaxone should be determined at regular intervals and dosage adjusted.<br />In patients undergoing dialysis, no additional supplementary dosage is required following the dialysis.<br />Plasma concentrations should be monitored, however, to determine whether dosage adjustments are<br />necessary, since the elimination rate in these patients may be reduced.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Ceftriaxone is contraindicated in patients with known hypersensitivity to beta-lactam antibiotics. In
patients hypersensitive to penicillin, the possibility of allergic cross-reactions should be borne in mind.
Hyperbilirubinaemic newborns and preterm newborns should not be treated with ceftriaxone. In vitro
studies have shown that ceftriaxone can displace bilirubin from its binding to serum albumin and
bilirubin encephalopathy can possibly develop in these patients.
Ceftriaxone is contraindicated in:
• premature newborns up to a corrected age of 41 weeks (weeks of gestation + weeks of life),
• full-term newborns (up to 28 days of age) with
- Jaundice, or who are hypoalbuminaemic or acidotic because these are conditions in which
bilirubin binding is likely to be impaired
- If they require (or are expected to require) IV calcium treatment, or calcium-containing
infusions because of the risk of precipitation of ceftriaxone-calcium (see sections 4.4, 4.8 and 6.2).
Contraindications of lidocaine must be excluded before intramuscular injection of ceftriaxone when
lidocaine is used as a solvent.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The stated dosage should not be exceeded.<br />If lidocaine is used as a solvent ceftriaxone solutions should only be used for intramuscular injection.<br />As with other cephalosporins, anaphylactic shock cannot be ruled out even if a thorough patient<br />history is taken.<br />Before therapy with ceftriaxone is instituted, careful inquiry should be made to determine whether the<br />patient has had any previous hypersensitivity reactions to ceftriaxone, cephalosporins, penicillins, or<br />other beta-lactam drugs. Ceftriaxone is contraindicated in patients who have had a previous<br />hypersensitivity reaction to any cephalosporin. It is also contraindicated in patients who have had a<br />previous immediate and/or any severe hypersensitivity reaction to any penicillin or to any other betalactam<br />drug (see section 4.3, Contra-indications). Ceftriaxone should be given with caution to patients<br />who have had any other type of hypersensitivity reaction to a penicillin or any other beta-lactam drug.<br />Care is required when administering ceftriaxone to patients who have previously shown<br />hypersensitivity to penicillins or other non-cephalosporin beta-lactam antibiotics, as occasional<br />instances of cross allergenicity between cephalosporins and these antibiotics have been recorded.<br />Anaphylactic shock requires immediate counter measures.<br />In severe renal impairment accompanied by hepatic insufficiency, dosage reduction is required as<br />outlined under Posology and method of administration.<br />Safety and effectiveness of ceftriaxone in neonates, infants and children have been established for the<br />dosages described under Dosage and administration. In vivo and in vitro studies have shown that<br />ceftriaxone, like some other cephalosporins, can displace bilirubin from serum albumin. Clinical data<br />obtained in neonates have confirmed this finding. Ceftriaxone should therefore not be used in neonates<br />(especially prematures) at risk of developing bilirubin encephalopathy.<br />Cases of fatal reactions with calcium-ceftriaxone precipitates in lungs and kidneys in premature and<br />full-term newborns aged less than 1 month have been described. At least one of them had received<br />ceftriaxone and calcium at different times and through different intravenous lines. In the available<br />scientific data, there are no reports of confirmed intravascular precipitations in patients, other than<br />newborns, treated with ceftriaxone and calcium-containing solutions or any other calcium-containing<br />products. In vitro studies demonstrated that newborns have an increased risk of precipitation of<br />ceftriaxone-calcium compared to other age groups.</p><p>In patients of any age ceftriaxone must not be mixed or administered simultaneously with any<br />calcium-containing IV solutions, even via different infusion lines or at different infusion sites.<br />However, in patients older than 28 days of age ceftriaxone and calcium-containing solutions may be<br />administered sequentially one after another if infusion lines at different sites are used or if the infusion<br />lines are replaced or thoroughly flushed between infusions with physiological salt-solution to avoid<br />precipitation. In patients requiring continuous infusion with calcium-containing TPN solutions,<br />healthcare professionals may wish to consider the use of alternative antibacterial treatments which do<br />not carry a similar risk of precipitation. If use of ceftriaxone is considered necessary in patients<br />requiring continuous nutrition, TPN solutions and ceftriaxone can be administered simultaneously,<br />albeit via different infusion lines at different sites. Alternatively, infusion of TPN solution could be<br />stopped for the period of ceftriaxone infusion, considering the advice to flush infusion lines between<br />solutions. (see sections 4.3, 4.8, 5.2 and 6.2).</p><p>Shadows which have been mistaken for gallstones, have been detected on sonograms of the<br />gallbladder, usually following doses of higher than the standard recommended dose (see section 4.8).<br />These shadows are, however, precipitates of calcium ceftriaxone which disappear on completion or<br />discontinuation of ceftriaxone therapy. Rarely have these findings been associated with symptoms. In<br />symptomatic cases, conservative nonsurgical management is recommended. Discontinuation of<br />ceftriaxone treatment in symptomatic cases should be at the discretion of the physician. These<br />shadows can appear in patients of any age, but are more likely in infants and small children who are<br />usually given a larger dose of ceftriaxone on a body weight basis. In children, doses greater than<br />80mg/kg body weight should be avoided because of the increased risk of biliary precipitates. There is<br />no clear evidence of gallstones or of acute cholecystitis developing in children or infants treated with<br />ceftriaxone.<br />Cephalosporins as a class tend to be absorbed onto the surface of the red cell membranes and react<br />with antibodies directed against the drug to produce a positive Coombs&#39; test and occasionally a rather<br />mild haemolytic anaemia. In this respect, there may be some cross-reactivity with penicillins.<br />Regular blood counts (haemoglobin, erythrocyte, leucocyte and platelet counts and screening for<br />prolongation of prothrombin time) should be carried out during treatment.<br />Cephalosporins may cause bleeding due to hypoprothrombinaemia and should be used with caution in<br />patients with renal or hepatic impairment, malnourished patients or those with low vitamin K levels<br />and also in patients receiving prolonged cephalosporin therapy who are at increased risk of developing<br />hypoprothrombinaemia.<br />Cases of pancreatitis, possibly of biliary obstruction aetiology, have been rarely reported in patients<br />treated with ceftriaxone. Most patients presented with risk factors for biliary stasis and biliary sludge,<br />e.g. preceding major therapy, severe illness and total parenteral nutrition. A trigger or cofactor role of<br />ceftriaxone-related biliary precipitation cannot be ruled out.<br />Superinfections with non-susceptible micro-organisms (such as yeasts, fungi) may occur as with other<br />anti-bacterial agents. A rare side-effect is pseudomembranous colitis which has resulted from infection<br />with Clostridium difficile during treatment with ceftriaxone.<br />Clostridium difficile associated diarrhea (CDAD) has been reported with use of nearly all antibacterial<br />agents, including ceftriaxone, and may range in severity from mild diarrhea to fatal colitis. Treatment<br />with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile.</p><p>C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin<br />producing strains of C.difficile cause increased morbidity and mortality, as these infections can be<br />refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all<br />patients who present with diarrhea following antibiotic use. Careful medical history is necessary since<br />CDAD has been reported to occur over two months after the administration of antibacterial agents.<br />If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C.difficile may need to<br />be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic<br />treatment of C.difficile, and surgical evaluation should be instituted as clinically indicated.<br />Each gram of ceftriaxone sodium contains approximately 3.6mmol sodium.<br />This should be taken into account for patients on a controlled sodium diet.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not use diluents containing calcium, such as Ringer&#39;s solution or Hartmann&#39;s solution, to<br />reconstitute ceftriaxone vials or to further dilute a reconstituted vial for IV administration because a<br />precipitate can form. Precipitation of ceftriaxone-calcium can also occur when ceftriaxone is mixed<br />with calcium-containing solutions in the same IV administration line. Ceftriaxone must not be<br />administered simultaneously with calcium-containing IV solutions, including continuous calciumcontaining<br />infusions such as parenteral nutrition via a Y-site. However, in patients other than neonates,<br />ceftriaxone and calcium-containing solutions may be administered sequentially, of one another, if the<br />infusion lines are thoroughly flushed between infusions with a compatible fluid. In vitro studies using<br />adult and neonatal plasma from umbilical cord blood demonstrated that neonates have an increased<br />risk of precipitation of ceftriaxone-calcium.<br />The elimination of ceftriaxone is not altered by probenecid.<br />Aminoglycoside antibiotics and diuretics: No impairment of renal function has so far been observed<br />after concurrent administration of large doses of ceftriaxone and potent diuretics (e.g.furosemide).<br />There is no evidence that ceftriaxone increases renal toxicity of aminoglycosides.<br />Alcohol: No effect similar to that of disulfiram has been demonstrated after ingestion of alcohol<br />subsequent to the administration of ceftriaxone. Ceftriaxone does not contain an N-methylthiotetrazole<br />moiety associated with possible ethanol intolerance and bleeding problems of certain other<br />cephalosporins.<br />Antibiotics: In an in vitro study, antagonistic effects have been observed with the combination of<br />chloramphenicol and ceftriaxone.<br />Anticoagulants: As ceftriaxone has an N-methylthiotriazine side-chain, it might have the potential to<br />cause hypoprothrombinaemia (Refer to section 4.8, Undesirable effects) resulting in an increased risk<br />of bleeding in patients treated with anticoagulants.<br />Oral Contraceptives: Ceftriaxone may adversely affect the efficacy of oral hormonal contraceptives.<br />Consequently, it is advisable to use supplementary (non-hormonal) contraceptive measures during<br />treatment and in the month following treatment.<br />Based on literature reports ceftriaxone is incompatible with amsacrine, vancomycin, fluconazole and<br />aminoglycosides.</p><p>Interference with Laboratory Tests:<br />In patients treated with ceftriaxone, the Coombs&#39; test may in rare cases be false-positive.<br />Ceftriaxone, like other antibiotics, may result in false-positive tests for galactosaemia. Likewise, nonenzymatic<br />methods such as copper reduction methods (Benedict&#39;s, Fehling&#39;s or Clinitest) for glucose<br />determination in urine may give false-positive results. For this reason, urine-glucose determination<br />during therapy with ceftriaxone should be carried out enzymatically.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pregnancy:<br />Ceftriaxone crosses the placental barrier. Safety in human pregnancy has not been established.<br />Reproductive studies in animals have shown no evidence of embryotoxicity, fetotoxicity,<br />teratogenicity or adverse effects on male or female fertility, birth or perinatal and postnatal<br />development. In primates, no embryotoxicity or teratogenicity has been observed. Therefore<br />ceftriaxone should not be used in pregnancy unless absolutely indicated.<br />Lactation:<br />Low concentrations of ceftriaxone are excreted in human milk. Caution should be exercised when<br />ceftriaxone is administered to a nursing woman</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Ceftriaxone has been associated with dizziness, which may affect the ability to drive or operate<br />machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The undesirable effects usually are mild and short-term.<br />Rarely, severe, and in some cases fatal, adverse reactions have been reported in preterm and full term<br />newborns (aged &lt;28 days) who had been treated with intravenous ceftriaxone and calcium.<br />Precipitations of ceftriaxone-calcium salt have been observed in lung and kidneys post-mortem. The<br />high risk of precipitation in newborns is due to their low blood volume and the longer half-life of<br />ceftriaxone compared with adults (see sections 4.3, 4.4 and 5.2).<br />Ceftriaxone must not be mixed or administered simultaneously with calcium-containing solutions or<br />products, even via different infusion lines.<br />Gastrointestinal<br />Common (&ge; 1% - &lt;10%): Loose stools or diarrhoea (diarrhoea may sometimes be a symptom of<br />pseudomembranous colitis, see 4.4 Special warnings and precautions for use), nausea, vomiting,<br />stomatitis and glossitis.<br />Rare (&ge; 0.01% - &lt; 0.1%): Abdominal pain.<br />Infections<br />Superinfection caused by microorganisms non-susceptible to ceftriaxone such as yeasts, fungi<br />(mycosis of the genital tract) or other resistant microorganisms may develop. Pseudomembranous<br />colitis is a rare undesirable effect caused by infection with Clostridium difficile during treatment with<br />ceftriaxone. Therefore, the possibility of the disease should be considered in patients who present<br />with diarrhoea following antibacterial agent use.</p><p>Hypersensitivity<br />Uncommon (&ge; 0.1% - &lt; 1%): Maculopapular rash or exanthema, pruritus, urticaria, oedema,<br />shivering and anaphylactic or anaphylactoid reactions (e.g. bronchospasm) and allergic dermatitis<br />have occurred.<br />Rare (&ge; 0.01% - &lt; 0.1%): Drug fever, shivering. Anaphylactic-type reactions such as bronchospasm<br />are rare.<br />Very rare (&lt; 0.01%): Isolated cases of severe cutaneous adverse reactions (erythema multiforme,<br />Stevens Johnson Syndrome and Lyell&#39;s Syndrome/toxic epidermal necrolysis) have been reported.<br />Blood and lymphatic system disorders<br />Common (&ge;1% - &le;10%):<br />Haematological reactions have included anaemia (all grades), haemolytic anaemia, granulocytopenia,<br />leucopenia, neutropenia, thrombocytopenia and eosinophilia. Coagulation disorders have been<br />reported as very rare side effects.<br />Unknown frequency of agranulocytosis (&lt;500/mm3) has been reported, mostly after 10 days of<br />treatment and following total doses of 20g or more.<br />There have been rare reports of fatal haemolysis in association with ceftriaxone. Ceftriaxone has<br />rarely been associated with prolongation of prothrombin time, however, bleeding and bruising due to<br />hypoprothrombinaemia may be more prevalent in patients with renal or hepatic impairment,<br />malnourished patients or those with low vitamin K levels and patients receiving prolonged<br />ceftriaxone therapy.</p><p>Central Nervous system<br />Rare (&ge; 0.01% - &lt; 0.1%): Headache, vertigo and dizziness.<br />Administration of high doses of cephalosporins, particularly in patients with renal insufficiency, may<br />result in convulsions.<br />Renal and Urinary<br />Rare (&ge; 0.01% - &lt; 0.1%): Glycosuria, oliguria, haematuria, increase in serum creatinine.<br />Very rare (&lt; 0.01%): Cases of renal precipitation have been reported, mostly in children older than 3<br />years and who have been treated with either high daily doses (e.g.&ge; 80mg/kg/day) or total doses<br />exceeding 10 grams and presenting other risk factors (e.g. fluid restrictions, confinement to bed, etc.).<br />The risk of precipitate formation is increased in immobilized or dehydrated patients. This event may<br />be symptomatic or asymptomatic, may lead to renal insufficiency and anuria, and is reversible upon<br />discontinuation of ceftriaxone.<br />Acute renal tubular necrosis may occur rarely with ceftriaxone.</p><p>Hepatobiliary system<br />Rare (&ge; 0.01% - &lt; 0.1%): Hepatitis and/or cholestatic jaundice, increase in liver enzymes.Transient<br />elevations in liver function tests have been reported in a few cases.<br />Shadows which have been mistaken for gallstones, but which are precipitates of calcium ceftriaxone,<br />have been detected by sonograms. These abnormalities are commonly observed after an adult daily<br />dose of two grams per day or more, or its equivalent in children; these abnormalities were particularly<br />observed in children with an incidence of above 30% in isolated reports. At doses of two grams a day<br />or above these biliary precipitates may occasionally cause symptoms. Should patients develop<br />symptoms, non-surgical management is recommended and discontinuation of ceftriaxone should be<br />considered. The evidence suggests biliary precipitates usually disappear once ceftriaxone has been<br />stopped. The risk of biliary precipitates may be increased by treatment duration greater than 14 days,<br />renal failure, dehydration or total parenteral nutrition.<br />Pancreas<br />Very rare (&lt; 0.01%): There have been isolated reports of pancreatitis although a causal relationship to<br />ceftriaxone has not been established.<br />Local effects<br />Rare (&ge; 0.01% - &lt; 0.1%): Pain or discomfort may be experienced at the site of intramuscular injection<br />immediately after administration but is usually well tolerated and transient. Intramuscular injection<br />without lidocaine solution is painful. Local phlebitis has occurred rarely following intravenous<br />administration but can be minimised by slow injection over at least 2-4 minutes.</p><p>Influence on diagnostic tests<br />In patients treated with ceftriaxone the Coombs&#39; test rarely may become false-positive. Ceftriaxone,<br />like other antibiotics, may result in false-positive tests for galactosemia.<br />Likewise, nonenzymatic methods for the glucose determination in urine may give false-positive<br />results. For this reason, urine-glucose determination during therapy with ceftriaxone should be done<br />enzymatically.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In the case of overdose nausea, vomiting, diarrhoea, can occur. Ceftriaxone concentration cannot be<br />reduced by haemodialysis or peritoneal dialysis. There is no specific antidote. Treatment is<br />symptomatic</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>General Properties<br />ATC classification: J01DD04</p><p>Mode of action<br />Ceftriaxone has bactericidal activity resulting from the inhibition of bacterial cell wall synthesis<br />ultimately leading to cell death. Ceftriaxone is stable to a broad range of bacterial &beta;-lactamases.<br />Mechanism of resistance<br />Ceftriaxone is stable to a wide range of both Gram-positive and Gram-negative beta-lactamases,<br />including those which are able to hydrolyse advanced generation penicillin derivatives and other<br />cephalosporins. Resistance to ceftriaxone is encoded mainly by the production of some beta-lactam<br />hydrolysing enzymes (including carbapenemases and some ESBLs) especially in Gram-negative<br />organisms. For Gram-positive organisms such as S. aureus and S. pneumoniae, acquired resistance is<br />mainly encoded by cell wall target site alterations. Outside of the advanced generation parenteral<br />cephalosporins, cross-resistance to other drug classes is generally not encountered.<br />Breakpoints<br />Current MIC breakpoints used to interpret ceftriaxone susceptibility data are shown below. Values<br />quoted comprise mg/L (MIC testing).<br />European Committee on Antimicrobial Susceptibility Testing (EUCAST) Clinical MIC Breakpoints<br />(V1.1, 31/03/2006)</p><table border="1" cellspacing="1" cellpadding="0" style="width:500px"><tbody><tr><td>&nbsp;</td><td><p>Susceptible/Resistant</p></td></tr><tr><td><p>Enterobacteriaceae<sup>2</sup></p></td><td><p>1/2</p></td></tr><tr><td><p>Pseudomonas</p></td><td><p>--</p></td></tr><tr><td><p>Acinetobacter</p></td><td><p>--</p></td></tr><tr><td><p>Staphylococcus<sup>3</sup></p></td><td><p>Note<sup>3</sup></p></td></tr><tr><td><p>Enterococcus</p></td><td><p>--</p></td></tr><tr><td><p>Streptococcus A, B, C, G</p></td><td><p>0.5/0.5<sup>4</sup></p></td></tr><tr><td><p>Streptococcus pneumoniae</p></td><td><p>0.5/2<sup>4</sup></p></td></tr><tr><td><p>Haemophilus influenzae</p></td><td><p>0.12/0.12<sup>4</sup></p></td></tr><tr><td><p>Moraxella Catarrhalis</p></td><td>&nbsp;</td></tr><tr><td><p>Neisseria gonorrhoea</p></td><td><p>0.12/0.12<sup>4</sup></p></td></tr><tr><td><p>Neisseria Meningitidis</p></td><td><p>0.12/0.12<sup>4</sup></p></td></tr><tr><td><p>Gram-negative, anaerobes</p></td><td><p>--</p></td></tr><tr><td><p>Non-species related breakpoints<sup>1</sup></p></td><td><p>1/2</p></td></tr><tr><td><p>S&lt;/&gt;R</p></td><td>&nbsp;</td></tr></tbody></table><p>1. Non-species related breakpoints have been determined mainly on the basis of PK/PD data and are<br />independent of MIC distributions of specific species. They are for use only for species that have not<br />been given a species-specific breakpoint and not for those species where susceptibility testing is not<br />recommended (marked with -- or IE in the table).<br />2. The cephalosporin breakpoints for Enterobacteriaceae will detect resistance mediated by most<br />ESBLs and other clinically important beta-lactamases in Enterobacteriaceae. However, some ESBLproducing<br />strains may appear susceptible or intermediate with these breakpoints. Laboratories may<br />want to use a test which specifically screens for the presence of ESBL.<br />3. Susceptibility of staphylococci to cephalosporins is inferred from the methicillin susceptibility<br />(except ceftazidime which should not be used for staphylococcal infections).<br />4. Strains with MIC values above the S/I breakpoint are very rare or not yet reported. The identification<br />and antimicrobial susceptibility tests on any such isolate must be repeated and if the result is confirmed<br />the isolate sent to a reference laboratory. Until there is evidence regarding clinical response for<br />confirmed isolates with MIC above the current resistant breakpoint (in italics) they should be reported<br />resistant.<br />-- = Susceptibility testing not recommended as the species is a poor target for therapy with the drug.<br />IE = There is insufficient evidence that the species in question is a good target for therapy with the<br />drug.<br />RD = rationale document listing data used by EUCAST for determining breakpoints.</p><p>Susceptibility<br />The prevalence of acquired resistance may vary geographically and with time for selected species and<br />local information on resistance is desirable, particularly when treating severe infections. As necessary,<br />expert advice should be sought when the local prevalence of resistance is such that the utility of the<br />agent in at least some types of infections is questionable.<br />Ceftriaxone susceptibility among Gram-positive and Gram-negative bacterial species in Europe from<br />January 1999-December 2001:</p><p><strong>Commonly susceptible species (i.e. resistance &lt; 10% in all EU Member States)</strong></p><p>Gram-Positive aerobes:<br />MSa coagulase negative Staphylococcus spp. (including S. epidermis)*<br />MSbStaphylococcus aureus*<br />Group B (Streptococcus agalactiae)<br />Streptococcus bovis<br />Streptococcus pneumoniae*</p><p>Group A Streptococcus (Streptococcus pyogenes)*<br />Streptococcus viridans*<br />Gram-Negative aerobes:<br />Citrobacter spp. (including C.freundii)<br />Escherichia coli*<br />Haemophilus influenzae (including beta-lactamase positive isolates)c*<br />Haemophilus para-influenzae*<br />Klebsiella spp. (including K. pneumoniae and K. oxytoca)*<br />Moraxella catarrhalis*<br />Morganella morganii*<br />Neisseria gonorrhoea (including penicillin-resistant isolates)*<br />Neisseria meningitidis*<br />Proteus spp. (including P. mirabilis and P. vulgaris)*<br />Salmonella spp. (including S. typhimurium)<br />Serratia spp. (including Serratia marsescens)*<br />Shigella spp.<br />Anaerobes:<br />Clostridium spp.*</p><p>&nbsp;</p><p><strong>Species for which acquired resistance may be a problem (i.e. resistance 10% in at least one EU<br />Member State)</strong></p><p>Gram-Negative aerobes:<br />Pseudomonas aeruginosa +<br />Enterobacter spp. (including E. aerogenes and E. cloacae)*+<br />Acinetobacter spp. (including A. baumanii and A. calcoaceticus)*+<br />Anaerobes:</p><p>Bacteroides spp.*<br />Peptostreptococcus spp.*</p><p>&nbsp;</p><p><strong>Inherently resistant organisms</strong></p><p>Gram-Positive aerobes:<br />MRd coagulase negative Staphylococcus spp. (including S. epidermidis)<br />MReStaphylococcus aureus<br />Enterococcus spp.<br />Gram-Negative aerobes:<br />Listeria monocytogenes<br />Mycoplasma spp.<br />Stenotrophomonas maltophilia<br />Ureaplasma urealyticum<br />Others:<br />Chlamydia spp.</p><p>&nbsp;</p><p>aMethicillin-susceptible Coagulase-Negative Staphylococcus<br />bMethicillin-susceptible Staphylococcus aureus<br />cNon-susceptible range (no resistant breakpoints defined)<br />dMethicillin-resistant Coagulase-Negative Staphylococcus<br />eMethicillin-resistant Staphylococcus aureus<br />* Species for which the efficacy of ceftriaxone has been demonstrated both in vitro and in vivo<br />+ Species for which high rates of resistance have been observed in one or more regions within the EU</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of ceftriaxone are largely determined by its concentration-dependent binding to<br />plasma albumin. The plasma free (unbound) fraction of the drug in man is approximately 5% over most<br />of the therapeutic concentration range, increasing to 15% at concentrations of 300mg/l. Owing to the<br />lower albumin content, the proportion of free ceftriaxone in interstitial fluid is correspondingly higher<br />than in plasma.</p><p>Plasma concentrations: Mean peak concentrations after bolus intravenous injection are about 120mg/l<br />following a 500mg dose and about 200mg/l following a 1g dose; mean levels of 250mg/l are achieved<br />after infusion of 2g over 30 minutes. Intramuscular injection of 500mg ceftriaxone in 1% Lidocaine<br />Injection BP produces mean peak plasma concentrations of 40-70 mg/l within one hour.<br />Bioavailability after intramuscular injection is 100%.<br />Excretion: Ceftriaxone is eliminated mainly as unchanged drug, approximately 60% of the dose being<br />excreted in the urine (almost exclusively by glomerular filtration) and the remainder via the biliary and<br />intestinal tracts. The total plasma clearance is 10-22 ml/min. The renal clearance is 5-12 ml/min. A<br />notable feature of ceftriaxone is its relatively long plasma elimination half-life of approximately eight<br />hours which makes single or once daily dosage of the drug appropriate for most patients. The half-life<br />is not significantly affected by the dose, the route of administration or by repeated administration.<br />Pharmacokinetics in special clinical situations: In the first week of life, 80% of the dose is excreted in<br />the urine; over the first month, this falls to levels similar to those in the adult. In infants aged less than<br />8 days the average elimination half-life is usually two to three times longer than that of young adults.<br />In elderly persons aged over 75 years, the average elimination half-life is usually two to three times<br />longer that in the young adult group. As with all cephalosporins, a decrease in renal function in the<br />elderly may lead to an increase in half-life. Evidence gathered to date with ceftriaxone however,<br />suggests that no modification of the dosage regimen is needed.<br />In patients with renal or hepatic dysfunction, the pharmacokinetics of ceftriaxone are only minimally<br />altered and the elimination half-life is only slightly increased. If kidney function alone is impaired,<br />biliary elimination of ceftriaxone is increased; if liver function alone is impaired, renal elimination is<br />increased.<br />Cerebrospinal fluid: Ceftriaxone crosses non-inflamed and inflamed meninges, attaining<br />concentrations 4-17% of the simultaneous plasma concentration.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no preclinical safety data of relevance to the prescriber that are additional to those included in<br />other sections</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The only ingredient is the active ingredient Ceftriaxone Sodium.<br />Solvent: Lidocaine hydrochloride</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Solutions containing ceftriaxone should not be mixed with or added to solutions containing other agents<br />except 1% Lidocaine Injection BP (for intramuscular injection only). In particular, diluents containing<br />calcium, (e.g. Ringer&#39;s solution, Hartmann&#39;s solution) should not be used to reconstitute ceftriaxone<br />vials or to further dilute a reconstituted vial for IV administration because a precipitate can form.<br />Ceftriaxone must not be mixed or administered simultaneously with calcium containing solutions (see<br />section 4.2, 4.3, 4.4 and 4.8). Based on literature reports, ceftriaxone is not compatible with amsacrine,</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                3 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30o C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A carton containing one filled vial, one 5ml Lidocaine HCL injection ampoule and a folded leaflet</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The reconstituted solution is stable for 6 hours at room temperature (below 30&deg;C)<br />or for 24 hours in refrigerator (2-8&deg;C).<br />Ceftriaxone should not be mixed in the same syringe with any drug other than 1 % lidocaine<br />hydrochloride solution (for intramuscular injection only).<br />Do not use diluents containing calcium, such as Ringer&rsquo;s solution or Hartmann&rsquo;s solution, to<br />reconstitute Ceftriaxone. Particulate formation can result.<br />Intramuscular injection: Triaxone 0.5g should be dissolved in 2 ml of 1 % lidocaine hydrochloride<br />solution. Triaxone 1g should be dissolved in 3.5 ml of 1 % lidocaine hydrochloride solution. The<br />solution should be administered by deep intramuscular injection. Dosages greater than 1 g should be<br />divided and injected at more than one site. Solutions of lidocaine should not be administered<br />intravenously.<br />Intravenous injection: Triaxone 0.5 g is dissolved in 5 ml and Triaxone 1.0 g in 10 ml of water for<br />injections. The injection should be administered over at least 2 &ndash; 4 minutes, directly into the vein or via<br />the tubing of an intravenous infusion.<br />Intravenous infusion: Triaxone 1g should be dissolved in 20 to 40 ml of one of the following calciumfree<br />infusion solutions: Sodium chloride 0.9%, sodium chloride 0.45% and glucose 2.5%, glucose 5 %<br />or 10%, dextran 6% in glucose 5%, hydroxyethyl starch 6-10% infusions. See also the information<br />included in section 6.2. The infusion should be administered over at least 30 minutes.<br />When reconstituted for intramuscular or intravenous injection, the white to yellowish-orange crystalline<br />powder gives a pale yellow to amber solution.<br />Reconstituted solutions should be inspected visually. Only clear solutions free of visible particles<br />should be used. The reconstituted product is for single use only and any unused solution must be<br />discarded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Abbott Laboratories GmbH
Freundallee 9A
30173 Hannover
Germany
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                July 2016
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>